OCS

OculisD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

15%

Probability

Target price

$21.00

+70.9% vs current

Most likely

Base case

50%

Probability

Target price

$13.00

+5.8% vs current

B-

Bear case

35%

Probability

Target price

$5.00

-59.3% vs current

AI sentiment snapshot

Latest data as of 2026-06-02

AI commentary

The reaction is negative: secondary coverage flagged a more than 20% drop after the DME miss, and the company source confirms the core issue was endpoint failure rather than a balance-sheet problem. Cash runway into 2H 2029 reduces near-term financing risk, but coverage is thin and analyst revision data are unavailable, so this stays a cautious monitoring setup rather than a high-conviction bullish re-entry.

RankAlpha Sentiment Codex - 2026-06-02

Open full AI memo

Evidence flagged

future-looking catalyst discovery is still SERP-only and has not been confirmed by a primary source

Impact

tentative

Confidence

AI events

2026-05-29eventDIAMOND Phase 3 missed the primary DME vision endpointHigh impact

Company-published DIAMOND-1 and DIAMOND-2 topline results showed OCS-01 did not meet the primary BCVA endpoint or the key at least 15-letter gain endpoint, and Oculis said it does not plan to pursue an FDA filing for DME [#PR-EARNINGS-2026-05-29].

2026-06-06catalystPost-readout selloff may keep sentiment volatileMedium impact

Secondary coverage flagged a more than 20% drop after the trial miss, so near-term trading could stay headline-driven while the market digests how much value now rests on the remaining pipeline [#SERP-1].

2026-12-31catalystPipeline refocus keeps Privosegtor and Licaminlimab fundedHigh impact

Management is reallocating resources to Privosegtor PIONEER in optic neuropathies and Licaminlimab PREDICT-1 in dry eye, with $278 million of cash and runway into 2H 2029 supporting the remaining late-stage portfolio [#PR-EARNINGS-2026-05-29].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology